Herpetoviridae (e.g., Herpesvirus, Mareks Disease Virus, Laryngotracheitis Virus, Infectious Bovine Rhinotracheitis Virus (ibr), Infectious Pustular Vulvovaginitis Virus, Bovine Herpes Virus Type 1, Aujeszkys Disease Virus, Feline Rhinotracheitis Virus, Feline Herpes Virus, Etc.) Patents (Class 424/229.1)
  • Patent number: 10449246
    Abstract: The present disclosure provides a PRV gB protein fragment, or a conservative variant or active fragment thereof, the gB protein fragment has a high level of expression, the subunit vaccine antigen prepared from the gB protein fragment has a better immune effect than a subunit vaccine antigen prepared from gB protein. The invention also provides a preparation method of a subunit vaccine by using the gB protein fragment alone, or the gB protein fragment together with gD protein. This vaccine has a simple preparation method and provides excellent protection against disease caused by the porcine pseudorabies virus.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: October 22, 2019
    Assignee: Pulike Biological Engineering, Inc.
    Inventors: Kegong Tian, Tongyan Wang, Jinzhong Sun, Xuke Zhang
  • Patent number: 10246685
    Abstract: The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: April 2, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Yukari Ishihara, Motoyuki Esaki, Shuji Saitoh
  • Patent number: 10201604
    Abstract: This disclosure describes a modified live infectious laryngotracheitis virus (ILTV) developed from a strain of ILTV grown at a reduced incubation temperature, vaccines that include the modified live ILTV, methods for producing the live modified ILTV, and methods that include administering the modified ILTV to a subject.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: February 12, 2019
    Assignee: UNIVERSITY OF DELAWARE
    Inventors: Jack Gelb, Jr., Brian S. Ladman, Miguel Ruano
  • Patent number: 9642905
    Abstract: The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomization of the vaccine.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 9, 2017
    Assignee: Intervet Inc.
    Inventor: Antonius Arnoldus Christiaan Jacobs
  • Patent number: 9623059
    Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 18, 2017
    Assignees: New York University, Benevir Biopharm, Inc.
    Inventors: Ian J. Mohr, Matthew C. Mulvey
  • Patent number: 9114108
    Abstract: The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: August 25, 2015
    Assignee: MERIAL, INC.
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz
  • Patent number: 9044420
    Abstract: Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: June 2, 2015
    Assignee: IMMUNE DESIGN CORP.
    Inventors: Thomas W. Dubensky, Jr., Scott H. Robbins
  • Patent number: 8986987
    Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: March 24, 2015
    Assignee: Intervet Inc.
    Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
  • Patent number: 8986707
    Abstract: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 24, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Antonie Neubauer, Christina Ziegler
  • Patent number: 8986706
    Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 24, 2015
    Assignee: Merial, Inc.
    Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
  • Publication number: 20150050307
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 19, 2015
    Inventors: Christopher James Nicolai, Semih U. Tareen
  • Publication number: 20150017121
    Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
    Type: Application
    Filed: October 10, 2012
    Publication date: January 15, 2015
    Applicant: UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Johannes Vom Berg
  • Patent number: 8932604
    Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 13, 2015
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
  • Patent number: 8916371
    Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 23, 2014
    Assignee: Merial Limited
    Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
  • Patent number: 8911747
    Abstract: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: December 16, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey M. Friedman, Elizabeth E. Brittle, Fushan Wang
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Publication number: 20140348875
    Abstract: The present invention relates to a recombinant Koi herpesvirus (KHV), methods for the production of such KHV, cells comprising such KHV and the use of such KHV as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by Koi herpesvirus in carp such as Cyprinus carpio carpio or Cyprinus carpio koi.
    Type: Application
    Filed: December 20, 2012
    Publication date: November 27, 2014
    Inventor: Alain Vanderplasschen
  • Patent number: 8877211
    Abstract: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5?30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5?30-32 CT-null/gE CT?/Us9? virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 4, 2014
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Shafiqul I. Chowdhury, Hui Yong Wei
  • Publication number: 20140322268
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 30, 2014
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. REED, Darrick CARTER
  • Patent number: 8871223
    Abstract: This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gI, Us9, or other proteins.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 28, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey Friedman, Elizabeth E. Zumbrun, Fushan Wang
  • Patent number: 8865185
    Abstract: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 21, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey Friedman, Elizabeth E. Zumbrun
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Publication number: 20140271710
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Sandhya BUCHANAN, Kevin O'CONNELL
  • Publication number: 20140271709
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Brad Eddy, Zhisong QIAO, Kevin O'Connell
  • Publication number: 20140255447
    Abstract: The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 11, 2014
    Applicant: BIOMUNE COMPANY
    Inventors: SHARAD DEVIDASRAO SAWARKAR, CHRISTOPHER PATRICK GULLY
  • Patent number: 8809047
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: August 19, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Feng Yao
  • Publication number: 20140205633
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 24, 2014
    Inventors: Carla Christina Schrier, Thomas Simon Ilg
  • Publication number: 20140199345
    Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 17, 2014
    Inventors: Carla Christina Schrier, Simon Ilg
  • Publication number: 20140193460
    Abstract: Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of Herpesvirus infections.
    Type: Application
    Filed: December 26, 2013
    Publication date: July 10, 2014
    Applicant: The Regents of the University of California
    Inventors: Deborah H. Spector, Christopher S. Morello, Kimberly A. Kraynyak
  • Patent number: 8765132
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: July 1, 2014
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 8747856
    Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: June 10, 2014
    Assignee: Ribovax Biotechnologies S.A.
    Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
  • Publication number: 20140147465
    Abstract: The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.
    Type: Application
    Filed: November 29, 2012
    Publication date: May 29, 2014
    Applicant: Merial Limited
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz
  • Publication number: 20140141043
    Abstract: Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 22, 2014
    Applicant: AUBURN UNIVERSITY
    Inventors: Haroldo Enrique Toro Guzman, Qingzhong Yu
  • Patent number: 8709730
    Abstract: Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and/or deubiquitinate ubiquitinated proteins and/or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and/or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and/or deubiquitination and/or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and/or management of viral infections.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: April 29, 2014
    Assignees: Icahn School of Medicine at Mount Sinai, Washington University School of Medicine
    Inventors: Adolfo Garcia-Sastre, Natalia Frias-Staheli, Herbert W. Virgin, Nadia Vicki Giannakopoulos
  • Patent number: 8709397
    Abstract: The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both ?134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: April 29, 2014
    Assignee: New York University
    Inventors: Ian Mohr, Matthew Mulvey
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20140065100
    Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Patent number: 8642045
    Abstract: It is intended to provide a virus vector by which an exogenous nucleotide sequence can be inserted and easily transferred into a mammalian host cell and a gene encoded by the exogenous nucleotide sequence can be expressed in the host cell, and which has a low risk of pathogenicity and is appropriately usable in gene therapy of mammals. Namely, a recombinant vector originating in HHV-6 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U5, U6, U7, U8, U24, and U25 regions of HHV-6; or a recombinant vector originating in HHV-7 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U7, U8, U24, U24a, and U25 regions of HHV-7.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: February 4, 2014
    Assignee: Virus Ikagaku Kenkyusho Inc.
    Inventor: Kazuhiro Konda
  • Publication number: 20140030292
    Abstract: This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.
    Type: Application
    Filed: October 11, 2011
    Publication date: January 30, 2014
    Applicant: Novartis AG
    Inventors: Michael Franti, Anders Lilja, Rebecca Loomis, Peter Mason
  • Patent number: 8637046
    Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: January 28, 2014
    Assignees: Cornell University, Novartis AG
    Inventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
  • Publication number: 20130337009
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of infectious diseases. In particular, the invention relates to stimulating an immune response in a subject to prevent or treat diseases by administering a DNA vaccine encoding regulatory elements derived from the caprine arthritis encephalitis goat lentivirus genome and at least one immunogenic molecule to the subject. The immunogenic molecules used with the present invention may be capable of stimulating an immune response to any infectious disease causing agent. In particular, the invention is useful for stimulating an immune response to infectious diseases caused by lentiviruses. For instance, the present invention is directed to a DNA vaccine for immunization against HIV.
    Type: Application
    Filed: February 20, 2013
    Publication date: December 19, 2013
    Applicant: IMMUNOGENETIX THERAPEUTICS, INC.
    Inventor: ImmunoGenetix Therapeutics, Inc.
  • Patent number: 8603480
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: December 10, 2013
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Patent number: 8586034
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: November 19, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Teresa Compton, Adam Lloyd Feire
  • Publication number: 20130302351
    Abstract: The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof.
    Type: Application
    Filed: January 31, 2012
    Publication date: November 14, 2013
    Applicant: EMORY UNIVERSITY
    Inventors: Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
  • Patent number: 8574594
    Abstract: The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.
    Type: Grant
    Filed: June 22, 2009
    Date of Patent: November 5, 2013
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Terry Hermiston, Fang Jin, Peter Kretschmer
  • Patent number: 8545848
    Abstract: The invention relates to neutralizing antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalized B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 1, 2013
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonia Lanzavecchia, Annalisa Macagno
  • Publication number: 20130224244
    Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
    Type: Application
    Filed: May 2, 2013
    Publication date: August 29, 2013
    Applicant: THE ROYAL VETERINARY COLLEGE
    Inventor: The Royal Veterinary College
  • Publication number: 20130202638
    Abstract: The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 8, 2013
    Inventors: Christian Thirion, Ulrich Koszinowski, Christian A. Mohr, Zsolt Ruzsics
  • Publication number: 20130195918
    Abstract: We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 1, 2013
    Inventors: Dennis J. O'Callaghan, ByungChul Ahn, Yunfei Zhang, Nikolaus Osterrieder